TScan Therapeutics
TCRX
73 hedge funds and large institutions have $62.9M invested in TScan Therapeutics in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 18 increasing their positions, 31 reducing their positions, and 12 closing their positions.
21% more capital invested
Capital invested by funds: $51.8M → $62.9M (+$11.1M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
2.35% less ownership
Funds ownership: 68.29% → 65.94% (-2.3%)
10% less funds holding
Funds holding: 81 → 73 (-8)
42% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 31
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$821K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$304K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$299K |
| 4 |
Two Sigma Advisers
New York
|
+$132K |
| 5 |
Two Sigma Investments
New York
|
+$96.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$690K |
| 2 |
Goldman Sachs
New York
|
-$530K |
| 3 |
BlackRock
New York
|
-$325K |
| 4 |
Millennium Management
New York
|
-$291K |
| 5 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$274K |
TCRX Hedge Fund Activity: Q3 2025 in Review
73 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2025, worth a combined $62.9M — up 21% from $51.8M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of TCRX and 5 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 18 added.
The largest buyer was Aberdeen Group, adding an estimated $821K. The largest seller was UBS Group, cutting an estimated $690K.
- 73 institutional investors held TScan Therapeutics (TCRX) as of Q3 2025, down from 81 in Q2 2025.
- Funds reported $62.9M of TScan Therapeutics stock for Q3 2025, up 21% quarter-over-quarter.
- 5 funds opened new TScan Therapeutics positions in Q3 2025 and 12 closed out, a net change of -7 holders.
- The largest TScan Therapeutics buyer in Q3 2025 was Aberdeen Group, an estimated $821K added.
- The largest TScan Therapeutics seller in Q3 2025 was UBS Group, an estimated $690K sold.
Based on aggregated 13F filings for Q3 2025.